Literature DB >> 9828942

Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996).

L A Trepanier1, A Van Schoick, W S Schwark, J Carrillo.   

Abstract

OBJECTIVE: To determine therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide.
DESIGN: Retrospective study. ANIMALS: 122 dogs with major motor epilepsy. PROCEDURE: Medical histories were collected for epileptic dogs treated with potassium bromide with or without phenobarbital sodium or primidone, from which serum was submitted for bromide analysis from May 1992 to May 1996 to the Therapeutic Drug Monitoring Program at Cornell University's College of Veterinary Medicine. A therapeutic response (improved seizure control) was defined as a > or = 50% reduction in seizure frequency following initiation of bromide treatment. Serum bromide and phenobarbital concentrations and therapeutic outcome were determined for all dogs.
RESULTS: 72% of epileptic dogs had a > or = 50% reduction in seizure frequency following initiation of treatment with potassium bromide. Discontinuation of barbiturate treatment was possible in 19% of those dogs originally treated with phenobarbital or primidone. Of those dogs continued on bromide and phenobarbital, 45% maintained seizure control with serum phenobarbital concentrations < 20 micrograms/ml. Significantly higher serum bromide concentrations were required when dogs were initially or eventually treated with bromide alone (mean bromide concentration, 1,906 micrograms/ml) compared with dogs treated with potassium bromide along with a barbiturate (mean bromide concentration, 1,621 micrograms/ml). CLINICAL IMPLICATIONS: When dogs are treated with bromide and phenobarbital, a reasonable therapeutic range for serum bromide concentrations is 810 to 2,400 micrograms/ml, and for bromide treatment alone, the range is 880 to 3,000 micrograms/ml. When phenobarbital is used in combination with bromide, a reasonable therapeutic range for serum phenobarbital concentrations is 9 to 36 micrograms/ml, although in some dogs treated with bromide, phenobarbital can eventually be discontinued.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828942

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  15 in total

1.  Lafora disease as a cause of visually exacerbated myoclonic attacks in a dog.

Authors:  Aubrey A Webb; Chantal McMillan; Cheryl L Cullen; Sarah E Boston; Julie Turnbull; Berge A Minassian
Journal:  Can Vet J       Date:  2009-09       Impact factor: 1.008

2.  International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe.

Authors:  Sofie F M Bhatti; Luisa De Risio; Karen Muñana; Jacques Penderis; Veronika M Stein; Andrea Tipold; Mette Berendt; Robyn G Farquhar; Andrea Fischer; Sam Long; Wolfgang Löscher; Paul J J Mandigers; Kaspar Matiasek; Akos Pakozdy; Edward E Patterson; Simon Platt; Michael Podell; Heidrun Potschka; Clare Rusbridge; Holger A Volk
Journal:  BMC Vet Res       Date:  2015-08-28       Impact factor: 2.741

3.  Imepitoin as novel treatment option for canine idiopathic epilepsy: pharmacokinetics, distribution, and metabolism in dogs.

Authors:  C Rundfeldt; A Gasparic; P Wlaź
Journal:  J Vet Pharmacol Ther       Date:  2014-03-10       Impact factor: 1.786

Review 4.  Treatment in canine epilepsy--a systematic review.

Authors:  Marios Charalambous; David Brodbelt; Holger A Volk
Journal:  BMC Vet Res       Date:  2014-10-22       Impact factor: 2.741

5.  Clinical risk factors associated with anti-epileptic drug responsiveness in canine epilepsy.

Authors:  Rowena M A Packer; Nadia K Shihab; Bruno B J Torres; Holger A Volk
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

6.  2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs.

Authors:  M Podell; H A Volk; M Berendt; W Löscher; K Muñana; E E Patterson; S R Platt
Journal:  J Vet Intern Med       Date:  2016-02-22       Impact factor: 3.333

Review 7.  Veterinary Compounding: Regulation, Challenges, and Resources.

Authors:  Gigi Davidson
Journal:  Pharmaceutics       Date:  2017-01-10       Impact factor: 6.321

8.  A double-blinded randomised dietary supplement crossover trial design to investigate the short-term influence of medium chain fatty acid (MCT) supplement on canine idiopathic epilepsy: study protocol.

Authors:  Benjamin Andreas Berk; Rowena Mary Anne Packer; Tsz Hong Law; Annette Wessmann; Andrea Bathen-Nöthen; Tarja Susanna Jokinen; Anna Knebel; Andrea Tipold; Ludovic Pelligand; Holger Andreas Volk
Journal:  BMC Vet Res       Date:  2019-05-30       Impact factor: 2.741

9.  Bromide toxicosis (bromism) secondary to a decreased chloride intake after dietary transition in a dog with idiopathic epilepsy: a case report.

Authors:  Marco Fantinati; Nathalie Priymenko; Maud Debreuque
Journal:  BMC Vet Res       Date:  2021-07-22       Impact factor: 2.741

10.  Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in a randomized controlled clinical study with long-term follow up.

Authors:  Chris Rundfeldt; Andrea Tipold; Wolfgang Löscher
Journal:  BMC Vet Res       Date:  2015-09-02       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.